US Urological Science

Targeted alpha therapy reshaping advanced prostate cancer

Advances in targeted alpha therapy for metastatic castration-resistant prostate cancer are reshaping care for men whose disease progresses despite androgen-deprivation therapy. mCRPC refers to metastatic disease that continues to grow while testosterone remains in the castrate range despite treatment removing or blocking androgen signalling. Radionuclides can deliver cytotoxic radiation directly to prostate cancer cells expressing prostate-specific membrane antigen, or PSMA.

Targeted alpha therapy pairs a cancer-targeting molecule with an alpha-emitting isotope. Alpha particles deposit dense energy over a microscopic distance, creating clustered DNA damage that tumour cells struggle to repair. Some radioligand regimens instead use beta emitters, which travel farther and produce a different radiation profile. Both fall under radioligand therapy, a distinction that matters when interpreting trial results, treatment names and side effects.

PSMA provides a useful biological handle because many prostate cancers retain it, although expression is not uniform. PSMA PET/CT helps identify disease likely to concentrate the therapy, while dosimetry aims to confirm that individual lesions receive an adequate absorbed dose. A favourable scan does not guarantee benefit, and PSA results cannot replace imaging, symptoms, previous treatments and assessment of overall health.

For Australian patients and clinicians, the question extends beyond whether the technology works. Regulatory approval, public subsidy, hospital capacity, travel and household responsibilities influence whether suitable therapy can be delivered safely. Evidence is evolving quickly, making current journal reviews and treatment protocols important. The strongest conclusions come from randomised trials and real-world registries, with treatment matched to the individual rather than to a drug label alone.

How targeted alpha therapy works

The biological argument for radioligand therapy is compelling because it can treat multiple metastatic sites while concentrating exposure in PSMA-expressing tissue. Unlike external-beam radiotherapy, which is directed at a defined region, systemic radionuclides circulate through the body. This may reach bone and other disseminated lesions, although normal salivary glands, kidneys and bone marrow also receive radiation and require surveillance. Treatment may involve an infusion followed by outpatient observation rather than daily attendance at a radiation centre.

Clinical development has moved from established agents to increasingly selective approaches. Radium-223 treats symptomatic bone metastases but does not target PSMA, whereas lutetium-177 PSMA-617 and investigational actinium-225 PSMA compounds do. Readers can compare evolving reports, protocols and reviews in the journal’s past journal issues, while distinguishing evidence for approved treatments from early-phase programmes. No isotope is universally superior; disease state, prior exposure and laboratory results guide selection.

Selecting the right patient

Patient selection begins with conventional staging and a PSMA PET/CT where available. Clinicians assess the percentage and distribution of PSMA expression, previous response to chemotherapy or androgen-receptor pathway inhibitors, and symptoms from bone, nodal or visceral disease. Performance status, marrow reserve, kidney function and competing illnesses are equally important. Imaging may be repeated after prior therapy because PSMA expression can change, and an unsuitable scan can redirect the entire treatment pathway.

Not all metastatic disease behaves alike. PSMA-negative lesions or neuroendocrine differentiation may respond poorly to PSMA-directed treatment, so FDG PET or biopsy can clarify the pattern when appropriate. Urinary symptoms also need separate attention. A man with haematuria, previous pelvic radiation or bladder instrumentation may require urologic review; Urological Science’s guide to urine cytology surveillance explains how cytology complements cystoscopy and imaging. Active bladder cancer usually changes sequencing and requires its own management plan.

Evidence behind the leading radioligands

Lutetium-177 PSMA-617 has the strongest randomised evidence in mCRPC. In the phase 3 VISION trial, median imaging progression-free survival was 8.7 months versus 3.4 months with standard care, while median overall survival in the PSMA-positive subgroup was 15.3 months versus 11.3 months. Subsequent studies have expanded the evidence base and informed earlier-line use in selected settings. These are population averages, however, and benefits depend on PSMA selection, previous treatment and the pace of progression.

Actinium-225 PSMA-617 is the leading next-generation alpha-emitting PSMA compound. Early studies report striking responses in heavily pretreated disease, but they remain smaller and less mature than the lutetium programme. Its shorter particle range and greater potency may improve tumour control while increasing the importance of kidney and marrow protection. Researchers are testing sequencing after lutetium, combinations with chemotherapy or immune therapies, and alternative alpha emitters. Head-to-head trials and longer follow-up are needed before safety and efficacy can be compared confidently.

Managing side effects and daily life

Radioligand therapy should not be confused with being symptom-free. Important effects include nausea, fatigue, dry mouth, altered taste, marrow suppression and transient kidney-function changes. Blood counts and renal function are checked before each cycle, with dose adjustment or delay when thresholds are not met. Antiemetics can prevent nausea, while dental care, hydration and oral hygiene help preserve comfort. Severity varies with the isotope, dose and earlier chemotherapy exposure.

Australian daily life can complicate outpatient treatment. Men may still drive to work, collect children from school or share a bathroom with a partner or young children. Written radiation-safety instructions should therefore be followed precisely, including flushing the toilet and handling urine contamination as directed. Partners who are pregnant or may become pregnant need specific advice. Persistent reflux, vomiting or difficulty swallowing merits assessment rather than automatic attribution to treatment; patient information on upper-GI endoscopy can explain an OGD, although oncology and urology teams decide when it is needed.

Access and delivery across Australia

Australian access operates through a mixture of regulation and reimbursement. The Therapeutic Goods Administration assesses radiopharmaceuticals under the Therapeutic Goods Act 1989, while the Pharmaceutical Benefits Scheme determines whether eligible medicines receive public subsidy and under what restrictions. Listings and criteria can change, and specialists should verify current requirements for the intended line of therapy, including whether prior androgen-receptor pathway inhibition and taxane chemotherapy are necessary. Eligible Medicare beneficiaries receive free public hospital care, with Medicare funding much of it; private health insurance and self-payment may affect where treatment occurs.

Delivery requires a licensed nuclear-medicine facility with radiopharmacy, imaging and medical follow-up, alongside licensing by state and territory radiation regulators. Major tertiary networks in Melbourne, Sydney, Brisbane, Perth and Adelaide provide the densest concentration of these services. Patients living in regional New South Wales, Queensland, Western Australia or the Northern Territory may face long drives, repeated scans and accommodation costs. Telehealth can support planning, although treatment and some imaging must occur in person.

Multidisciplinary review is crucial because urology, medical oncology, radiation oncology, nuclear medicine, radiology and pharmacy each influence sequencing. Treatment chosen without checking marrow reserve, renal function, neuroendocrine features and previous therapies may be less effective than the same agent used in a carefully designed sequence. For regional patients, coordinated appointments and local blood testing can reduce travel, while a specialist centre can provide a written monitoring plan for the treating GP and local team.

Where the field is moving next

The next wave is likely to move from a single agent for every patient toward theranostic planning: diagnose with a matched imaging agent, select the radionuclide, calculate organ and lesion doses, then reassess. Refined dosimetry may identify patients at risk of inadequate exposure, while novel carriers may improve tumour uptake or reduce kidney and salivary-gland exposure. Lead-212 and other emerging isotopes, alongside tandem or combination schedules, are being evaluated in trials rather than routine Australian practice.

Future trials must measure more than response rates. Meaningful outcomes include overall survival, time with good function, symptom control, quality of life and the burden of repeated hospital visits. For men considering an experimental option, specialist-reviewed clinical trial information can help clarify eligibility, location, travel and monitoring requirements. It should be discussed alongside standard options because trial access varies and evidence may be immature. National collaboration and shared registries remain important when effectiveness depends on both the isotope and execution of the entire pathway.

Patients with mCRPC should ask their medical oncologist or urologist whether PSMA PET imaging, molecular profiling or a radioligand referral could clarify treatment. Useful discussions include previous scans and PSA results, symptoms, blood counts, kidney function, earlier therapies and the practical effect of travel or home precautions. A nuclear-medicine or radionuclide-therapy centre can then assess whether the disease pattern, previous treatment and current health make an approved or trial-based programme appropriate.

Start the referral process through a urologist, medical oncologist or nuclear-medicine specialist with experience in radiopharmaceutical care. Bring a concise treatment timeline and imaging archive, and request a shared plan that includes toxicity review, response assessment and coordination with local services in Australia.